86 related articles for article (PubMed ID: 12114217)
1. The role of growth factors in the activity of pharmacological differentiation agents.
Matsui WH; Gladstone DE; Vala MS; Barber JP; Brodsky RA; Smith BD; Jones RJ
Cell Growth Differ; 2002 Jun; 13(6):275-83. PubMed ID: 12114217
[TBL] [Abstract][Full Text] [Related]
2. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Matsui W; Smith BD; Vala M; Beal N; Huff CA; Diehl LF; Jones RJ
Br J Haematol; 2005 Mar; 128(6):853-62. PubMed ID: 15755292
[TBL] [Abstract][Full Text] [Related]
3. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
4. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.
Lilly M; Tompkins C; Brown C; Pettit G; Kraft A
Cancer Res; 1990 Sep; 50(17):5520-5. PubMed ID: 2386956
[TBL] [Abstract][Full Text] [Related]
5. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
6. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
Roddie PH; Horton Y; Turner ML
Leukemia; 2002 Jan; 16(1):84-93. PubMed ID: 11840267
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression.
Clark CS; Konyer JE; Meckling KA
Exp Cell Res; 2004 Mar; 294(1):301-11. PubMed ID: 14980523
[TBL] [Abstract][Full Text] [Related]
8. The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells.
Gebbia V; Di Marco P; Miceli S; Reyes MB; Teresi M; Bonaccorso R; Citarrella P; Rausa L
Haematologica; 1988; 73(5):387-91. PubMed ID: 3143638
[No Abstract] [Full Text] [Related]
9. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Jones RJ; Sharkis SJ; Miller CB; Rowinsky EK; Burke PJ; May WS
Blood; 1990 Mar; 75(6):1319-23. PubMed ID: 2310830
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
11. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells.
Steube KG; Grunicke D; Pietsch T; Gignac SM; Pettit GR; Drexler HG
Leukemia; 1992 Oct; 6(10):1048-53. PubMed ID: 1405759
[TBL] [Abstract][Full Text] [Related]
12. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells.
Gore SD; Samid D; Weng LJ
Clin Cancer Res; 1997 Oct; 3(10):1755-62. PubMed ID: 9815560
[TBL] [Abstract][Full Text] [Related]
13. In vitro induction of inhibitory macrophage differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor and interferon-gamma from lineage phenotypes-negative c-kit-positive murine hematopoietic progenitor cells.
Ferret-Bernard S; Saï P; Bach JM
Immunol Lett; 2004 Feb; 91(2-3):221-7. PubMed ID: 15019293
[TBL] [Abstract][Full Text] [Related]
14. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Verheul HM; Qian DZ; Carducci MA; Pili R
Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
[TBL] [Abstract][Full Text] [Related]
15. Bryostatin 1: differentiating agent from the depths.
Stone RM
Leuk Res; 1997 May; 21(5):399-401. PubMed ID: 9225066
[No Abstract] [Full Text] [Related]
16. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Cheng YC; Lin H; Huang MJ; Chow JM; Lin S; Liu HE
Leuk Res; 2007 Oct; 31(10):1403-11. PubMed ID: 17445886
[TBL] [Abstract][Full Text] [Related]
17. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.
May WS; Sharkis SJ; Esa AH; Gebbia V; Kraft AS; Pettit GR; Sensenbrenner LL
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8483-7. PubMed ID: 3317410
[TBL] [Abstract][Full Text] [Related]
19. Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.
van der Hem KG; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1995 Sep; 19(9):651-7. PubMed ID: 7564476
[TBL] [Abstract][Full Text] [Related]
20. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
